Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Evolent Health, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Evolent Health, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:53 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628908-26-000086
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Expenses | ||||
| Cost of revenue (1) | 571,684 | 343,943 | 984,156 | 725,121 |
| Selling, general and administrative expenses (1) | 68,831 | 75,209 | 141,649 | 153,618 |
| Depreciation and amortization expenses | 21,566 | 23,141 | 43,121 | 47,199 |
| Loss on lease termination | — | — | — | 1,906 |
| Change in fair value of contingent consideration | — | 3,206 | — | 2,926 |
| Operating expenses | 662,081 | 445,499 | 1,168,926 | 930,770 |
| Operating loss | (9,561) | (1,171) | (20,160) | (2,793) |
Item 1. Financial Statements
FAQ
- What is Evolent Health, Inc.'s D&A?
- Evolent Health, Inc. (EVH) reported D&A of $21.57M in Q2 2026.
- How has Evolent Health, Inc.'s D&A changed year-over-year?
- Evolent Health, Inc.'s D&A decreased by 6.8% year-over-year, from $23.14M to $21.57M.
- What is the long-term trend for Evolent Health, Inc.'s D&A?
- Over 4 years (2021 to 2025), Evolent Health, Inc.'s D&A has grown at a 17.9% compound annual growth rate (CAGR), from $60.04M to $115.85M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Evolent Health, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude